Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 603 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in... November 16, 2022 News digest – targeted drug approval, microbubble ‘warheads’ and prostate cancer... June 27, 2020 Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,... February 12, 2022 Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... April 1, 2021 Load more HOT NEWS October is National Dental Hygiene Month A bug in the system – the difficulties of linking the... Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for... Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and...
